Discover 27 paid clinical trials in Hattiesburg, Mississippi. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 27
Active & Responsive
A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer
ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
for
Multiple Myeloma
Location: Hattiesburg MS, Germantown TN, Atlanta GA, Nashville TN,
Sponsor: Bristol-Myers Squibb
Sex: All
Age: 18+
Code: NCT05827016
Phase3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
for
Non-small Cell Lung Cancer
Location: Hattiesburg MS, Tyler TX, Houston TX, St. Petersburg FL,
Sponsor: Bristol-Myers Squibb
Sex: All
Age: 18+
Code: NCT06561386
Phase3, Recruiting
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
for
Follicular Lymphoma
Location: Hattiesburg MS, Mobile AL, Newnan GA, Marietta GA,
Sponsor: Celgene
Sex: All
Age: 18+
Code: NCT06911502
Phase3, Recruiting
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)